Dataset Information
Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.
Ontology highlight
ABSTRACT: Background
The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort.Methods
Incident melanoma cases were identified from the adverse events log. The expected number of cases was calculated, using the expected incidence rates and the number of person-years.Results
A total of 618 females and 1119 males were followed for 6452 person-years; 19 new melanoma cases were observed. The expected number was 5.29. The standardized event ratio compared to the general population was 3.6 (95% confidence interval, 2.2-5.6).Conclusions
The risk for developing melanoma was higher than expected in the NET-PD LS-1 cohort and was similar to the risk reported in earlier comparable clinical trial cohorts. Dermatologic screening may be useful in Parkinson's disease to identify melanoma at an early stage.
SUBMITTER: Constantinescu R
PROVIDER: S-EPMC4375545 | biostudies-literature | 2014 Feb
REPOSITORIES: biostudies-literature
Publications
Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.
Movement disorders : official journal of the Movement Disorder Society 20131203 2
<h4>Background</h4>The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort.<h4>Methods</h4>Incident melanoma cases were identified from the adverse events log. The expected number of cases was calculated, u ...[more]
